Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :19954294
Publication Date : //

Metastatic colorectal cancer: recent advances in its clinical management.


Colorectal cancer (CRC) is frequently complicated by metastatic disease, with the liver being the most common site of metastasis. Surgical resection is the only realistic cure for colorectal liver metastases; however only 10-25% of cases are initially resectable. The introduction of combination chemotherapy has improved survival rates by enabling 10-20% cases with previously unresectable hepatic metastases to become amenable to surgery. Recent results with the biologic agent bevacizumab, a chimeric human-mouse monoclonal antibody against VEGF, and cetuximab, a chimeric human-mouse monoclonal antibody against EGF receptor, have shown that they improve clinical surgical outcomes when added to current first-line regimens in patients with metastatic colorectal cancer. Dual biologic therapy in combination with chemotherapy has, however, yielded disappointing results. Identification of biological markers is expected to help determine which patients are most likely to respond to these newer agents and thus improve targeted therapy.

Authors : Barugel Mario E , Vargas Carlos , Krygier Waltier Gabriel ,

Related products :

Catalog number Product name Quantity
1240 Breast cancer, matched metastatic carcinoma and cancer adjacent normal breast tissue array, including TNM, clinical stage and pathology grade, 48 cases_ 96 cores,
1124 Breast cancer and matched metastatic carcinoma of lymph node tissue array, including TNM, clinical stage and pathology grade, 50 cases_100 cores, replacing BR1005
LC951 Lung cancer tissue array with normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 40 cases_95 cores
902 Lung cancer tissue array with matched lymph node metastatic tissue, including TNM, clinical stage and pathology grade, 40 cases_80 cores
OV951 Ovary cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 38 cases_95 cores,
CO951 Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases_95 cores
BR1005a Breast cancer and matched metastatic carcinoma of lymph node tissue array, including TNM, clinical stage and pathology grade, 50 cases_100 cores, replacing BR1005; ihc Anti-Actin confirmed
LC951 Lung cancer tissue array with normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 40 cases_95 cores; ihc Anti-Cytokeratin (CK) confirmed
KD951 Kidney cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage, pathology grade and survival data, 32 cases_95 cores
BR952 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores
LC817 Lung cancer tissue array with matched lymph node metastatic tissue, including TNM, clinical stage and pathology grade, 40 cases_80 cores; ihc Anti-Actin confirmed
OV951 Ovary cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 38 cases_95 cores,; ihc Anti-Actin confirmed
BR954 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores, replacing BR953; ihc
BR953 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores, replaced by BR954; ihc
CO951 Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases_95 cores, to be replaced by CO952; ihc Anti-Cytokeratin (C
BR951 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores, to be replaced by BR95
BR951 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores, replaced by BR952; ihc
BR953 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores, replacing BR952
KD951 Kidney cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage, pathology grade and survival data, 32 cases_95 cores; ihc Anti-Actin confirmed
CO952 Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases_95 cores, replacing CO951; ihc Anti-Cytokeratin (CK) confi
BR952 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores; ihc Anti-Actin confir
Metastasis - MET181 Metastatic cancer tissue array, 18 cases of metastatic cancers from 4 anatomic sites 2.5mm
ICTS-SER Cancer samples: Colorectal Cancer Serum-Adenocarcinoma Each
Tissues-123-COLORECTAL CANCER Human Tissues - COLORECTAL CANCER 1unit
orb61231 Capecitabine Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. For research use only. 1 g


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur | Gentaur





GENTAUR Ltd.
Unicorn House, Station Cl
Hertfordshire, Potters Bar EN6 1TL
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017
RIB 30004 00187 00010092253 10
BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG
IBAN FR76 3000 4001 8700 0100 9225 310
france@gentaur.com | Gentaur | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: +49 0241 40 08 90 86, +49 0241 95 78 94 78, +49 0241 40 08 90 86
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur | Gentaur